Schwab Strategic Trust Schwab Municipal Bond ETF (ARCA: SCMB)

Latest news for Schwab Strategic Trust Schwab Municipal Bond ETF (ARCA:SCMB)

To pursue its goal, the fund generally invests in securities that are included in the ICE AMT-Free Core U.S. National Municipal Index. The index measures the performance of U.S. dollar denominated investment grade tax-exempt debt publicly issued in the U.S. domestic market by U.S. states and territories as well as their political subdivisions. To be eligible for inclusion in the index, securities must be exempt from federal taxes and must not be subject to alternative minimum tax (AMT). In addition, securities must have at least a one-day remaining term to final maturity, a fixed coupon schedule (including zero coupon bonds) and an investment grade rating (based on the middle rating of Moodys, S&P and Fitch). If rated by all three agencies, two of the three ratings must be Baa3/BBB minus or higher; if rated by two agencies, the lowest rating must be Baa3/BBB minus or higher; and if rated by a single agency the security must be rated Baa3/BBB minus  or higher. Securities must have at least dollar 25 million currently outstanding face value and must be part of a deal with an original offering size of at least dollar 100 million. The index excludes certain types of securities, including, among others, step coupon securities, taxable municipal securities, floating rate notes and variable rate demand obligations or notes and private placements. The index is market capitalization weighted and

Schwab Municipal Bond ETF

Schwab Strategic Trust Schwab Municipal Bond ETF

Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares are trading lower in the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Thursday</a>.
The company <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42571377/lamb-weston-reports-second-quarter-fiscal-2025-results-board-approves-250-million-share-repurchase" rel="noreferrer noopener">reported second-quarter</a> adjusted earnings per share of 66 cents, missing the street view of $1.01. Quarterly sales of $1.60 billion (down 8% year-over-year) missed the analyst consensus estimate of $1.674 billion.
Volume dropped by 6 percent in the quarter due to weak global restaurant traffic and customer share losses, partially offset by gains.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42571954/why-is-penny-stock-canoo-falling-on-thursday" rel="noreferrer noopener">Why Is Penny Stock Canoo Falling On Thursday?</a>
The decline also reflects the company's decision last year to exit a lower-priced, lower-margin business in Europe to manage its customer and product mix better.
"Higher-than-expected manufacturing costs and softer volumes accounted for the shortfall, while price/mix and operating expenses were broadly in line with our targets for the quarter," said CEO Tom Werner.
"In terms of the broader operating environment, we expect challenging conditions to persist through the remainder of fiscal 2025 and into fiscal 2026," he added.
Net sales for the North America segment fell 8% to $1.072 billion, while the International segment decreased 6% to $528.8 million.&nbsp;
Adjusted gross profit&nbsp;declined by $134.9 million to $343.5 million versus the prior year quarter due to unfavorable price/mix, higher manufacturing costs per pound, and lower sales volumes.
Adjusted EBITDA declined by $95.0 million to $281.9 million compared to the prior year quarter, primarily due to lower net sales and adjusted gross profit.
As of November 24, the company had $79.0 million of cash and cash equivalents and $1.211 billion of available liquidity under its revolving credit facility.
Dividend Hike: In December 2024, the company approved an increase of $250 million in the company's existing $500 million share repurchase authorization under the program to an aggregate total of $750 million.
In addition, the board declared a quarterly dividend of 37 cents per share of Lamb Weston common stock, an increase of 1 cent.
The dividend is payable on February 28 to stockholders of record as of the close of business on January 31, 2025.
CEO Appointment: Lamb Weston announced the appointment of Michael J. Smith, currently COO, as<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42571401/lamb-weston-announces-appointment-of-michael-j-smith-as-president-and-chief-executive-officer" rel="noreferrer noopener"> President and CEO, effective January 3, 2025</a>. He will also join the company's Board of Directors.
Smith succeeds Thomas P. Werner, who is stepping down but will serve in an advisory role until August 31, 2025.
Outlook: Lamb Weston has lowered its FY25 outlook, now expecting net sales of $6.35 billion to $6.45 billion, down from a prior outlook of $6.6 billion-$6.8 billion. The analyst consensus estimate pegs at $6.65 billion.
The company also revised its adjusted EPS projection to $3.05-$3.20, below the previous outlook of $4.15-$4.35. The street view stands at $4.20.
Price Action: LW shares are trading lower by 20.80% to $61.97&nbsp;premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42569883/quantum-computing-rigetti-d-wave-skyrocket-up-to-300-in-5-sessions-after-google-unveils-willow-chip-but-analysts-urge-caution-not-every-tiktok-guitarist-is-the-next-taylor-swift" target="_blank" rel="noreferrer noopener">Quantum Computing, Rigetti, D-Wave Skyrocket Up To 300% In 5 Sessions After Google Unveils Willow Chip, But Analysts Urge Caution: ‘Not Every TikTok Guitarist Is The Next Taylor Swift'</a></li>
</ul>
Photo Courtesy of Lamb Weston

Earnings

Equities

News

Guidance

Markets

Movers

General

Lamb Weston Takes A Hit From High Manufacturing Costs And Softer Volumes, Expects Challenging Conditions Till 2026

Market-Moving Exclusives

Exclusives

VANI

EXCLUSIVE: Vivani Medical Tells Benzinga 'Study represents the first clinical application of NanoPortal, the Company's proprietary drug implant platform technology'

On Thursday, Vivani Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) initiated screening and enrollment at two centers in Australia for the first-in-human clinical trial, LIBERATE-1.
The trial investigates the safety, tolerability, and full pharmacokinetic profile of an exenatide implant.
Vivani&#8217;s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40704367/exclusive-vivani-medical-reveals-positive-preclinical-liver-fat-results-from-miniature-glp-1-impl" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity</a>
The study is the first clinical application of the company&#8217;s proprietary NanoPortal drug implant technology.
In September, the Bellberry Human Research Ethics Committee approved, and the Therapeutic Goods Administration in Australia formally acknowledged a first-in-human clinical trial of the company&#8217;s miniature, subdermal GLP-1 (exenatide) implant in obese and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41044242/exclusive-vivani-medical-advances-its-obesity-treatment-implant-with-new-clinical-trial-in-austra" rel="noreferrer noopener">overweight subjects</a>.
The trial will enroll participants who will be titrated on weekly semaglutide injections for 8 weeks before being randomized to receive a single administration of Vivani&#8217;s exenatide implant (n=8), weekly exenatide injections (n=8), or weekly 1 mg semaglutide injections (n=8) for 9-week treatment duration.
Weight changes will be measured. The company anticipates that top-line data will be available in mid-2025.
If available, Vivani intends to utilize research and development incentives and rebates from the Australian government to defray some of the costs from this clinical trial.
Since clinical studies conducted in Australia comply with the International Conference on Harmonization guidelines, data generated in Australia are generally acceptable to the FDA and other regulatory authorities.
Vivani anticipates using relevant clinical data generated in Australia to support regulatory submissions in other geographies, including the U.S.
Vivani&#8217;s pipeline also includes NPM-139 (semaglutide implant), which is also under development for chronic weight management in obese and overweight individuals.
Price Action: VANI stock is up 0.83% at $1.22 during the premarket session at last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a></li>
</ul>

Biotech

Health Care

EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia

35 analysts have shared their evaluations of Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">10</td>
<td align="right">14</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Fortinet, presenting an average target of $94.46, a high estimate of $115.00, and a low estimate of $68.00. Observing a 15.28% increase, the current average has risen from the previous average price target of $81.94. 
<img src="https://www.benzinga.com/files/images/story/2024/1734613221_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Fortinet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$103.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Underperform</td>
<td>$78.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$110.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shaul Eyal</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$100.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Dan Bergstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$97.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Stephen Bersey</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$111.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Yi Fu Lee</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Shaul Eyal</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fortinet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fortinet compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Fortinet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Fortinet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FTNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fortinet analyst ratings.</a>
<h2>Get to Know Fortinet Better</h2>
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 700,000 customers across the world.
<h3>Financial Insights: Fortinet</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Fortinet showcased positive performance, achieving a revenue growth rate of 13.0% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Fortinet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 35.8%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Fortinet's ROE excels beyond industry benchmarks, reaching 90.26%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Fortinet's ROA stands out, surpassing industry averages. With an impressive ROA of 6.39%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.09, Fortinet faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

FTNT

Expert Outlook: Fortinet Through The Eyes Of 35 Analysts

As Tesla Inc CEO Elon Musk predicts U.S. electricity demand will triple by 2045, American homeowners already struggle with soaring power bills that <a href="https://www.benzinga.com/top-stories/24/07/40043897/household-energy-bills-rose-over-50-in-3-states-over-past-5-years-but-remained-stable-in-this-region">increasingly influence real estate decisions</a>. According to a report issued by Realtor.com, the average monthly electric bill is now $137 nationwide, with regional variations complicating energy costs across the country.
&#8220;Utility bills are like the secret sauce no one talks about – they can make or break the deal,&#8221; Ron Myers, president of Ron Buys Florida Homes, said to Realtor.com. &#8220;A home with high energy bills can scare buyers away faster than a bad inspection.&#8221;
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-y2">The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl-y2"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Hawaii <a href="https://www.benzinga.com/real-estate/24/08/40369079/electricity-bills-now-surpassing-rent-in-california-why-are-prices-higher-than-anywhere-but-hawaii">leads the nation with average monthly bills of $213</a>, followed by Connecticut at $203 and Florida at $168. Meanwhile, Utah residents have the lowest average bills at $85, with New Mexico and Idaho rounding out the most affordable states at $91 and $107, respectively.
Musk's aggressive forecast far outpaces utility industry projections. According to a report by the Wall Street Journal, PG&amp;E anticipates a 70% demand increase over 20 years, while McKinsey expects demand to double by 2050. The gap between these estimates and current infrastructure investment raises concerns, as private power-sector construction declined last year despite manufacturing investment growth.
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks-y2">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
The impact already resonates at the household level. In Titusville, Florida, novelist Michael Allen told Realtor.com that his monthly bills are approaching $200 for his 1,200-square-foot home. &#8220;The sad part is, I don't ever see the electric bill coming back down. The price of living is getting too high and the electric company wants every dime they can get out of us," he said.
Solar adoption offers one potential solution, though installation costs ranging from $13,620 to $26,686 create barriers, according to Realtor.com. &#8220;Owned solar panels on a home are a huge selling point, especially on a resale when the seller has already gone through the hassle of having them installed and paid for them,&#8221; Cara Ameer, a Coldwell Banker agent in Los Angeles, was quoted in the report.
Trending: <a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf">&nbsp;</a>
More accessible alternatives include community solar programs, which Ben Airth, policy director at Freedom Forever, says can reduce bills by 5% to 20% annually without up-front costs. According to the Energy Department, basic efficiency measures like improved insulation can cut utilities by up to 20%.
Musk's predicted demand surge with already-strained household budgets indicates growing tension between electrification goals and consumer costs. As manufacturing investment and EV adoption accelerate, the pressure on America's power infrastructure – and homeowners' wallets – shows few signs of easing.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partnered with Amazon, Walmart &amp; Target announces the deadline to invest this year is 12/20. –  <a href="https://www.benzinga.com/money/mode-mobile-y2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>

Elon Musk Says U.S. Needs More Power – But Rising Electric Bills Are Already Shocking Buyers

EXCLUSIVE: Vivani Medical Tells Benzinga 'NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration'

EXCLUSIVE: Vivani Medical Tells Benzinga Co. Announces Initiation Of First In Human Clinical Trial With GLP-1 Implant In Obese And Overweight Individuals In Australia

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $128 price target.

Price Target

BMEA

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $128 Price Target

Stephens &amp; Co. analyst Jim Salera reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and maintains $164 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Darden Restaurants, Maintains $164 Price Target

Northcoast Research analyst Aaron Reed initiates coverage on Tennant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNC#NYSE">TNC</a>) with a Buy rating and announces Price Target of $125.

Initiation

Northcoast Research Initiates Coverage On Tennant with Buy Rating, Announces Price Target of $125

Rodman &amp; Renshaw analyst Tony Butler initiates coverage on TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) with a Buy rating and announces Price Target of $11.

HURA

Rodman & Renshaw Initiates Coverage On TuHURA Biosciences with Buy Rating, Announces Price Target of $11

WIIM

PHIO

Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee recommended dose escalation in its Phase 1B trial evaluating PH-762 for various advanced cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Baird analyst Tristan Gerra maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Outperform and lowers the price target from $150 to $130.

Baird Maintains Outperform on Micron Technology, Lowers Price Target to $130

Keybanc analyst Eric Heath downgrades C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from Sector Weight to Underweight and announces $29 price target.

Downgrades

Keybanc Downgrades C3.ai to Underweight, Announces $29 Price Target

Vladimir Putin, the President of Russia, has <a href="https://www.benzinga.com/news/global/24/11/41865062/putin-congratulates-trump-on-2024-election-victory-russian-leader-said-president-elect-manly-for-how-he-handled-assassination-attempt">shown his readiness to initiate talks</a> with the incoming U.S. President Donald Trump. 
What Happened: In his annual televised press conference held in Moscow, Putin stated his readiness to engage in dialogue with Trump,  <a href="https://www.bloomberg.com/news/articles/2024-12-19/putin-says-he-s-ready-to-meet-trump-hasn-t-seen-syria-s-assad">Bloomberg</a> on Thursday.
&#8220;I&#8217;m ready for it, of course, at any time. And I&#8217;ll be ready to meet if he wants,&#8221; he said. Trump, who is due to begin his second term as US president on Jan.20, has expressed his intent to resolve the ongoing war between Russia and Ukraine, which has been ongoing for nearly three years.
Trump Campaign did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/12/42522048/jim-cramer-warns-nvidias-vicious-and-fast-reversal-is-coming-amid-174-surge-this-year-and-china-antitrust-probe?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Warns Nvidia&#8217;s &#8216;Vicious&#8217; And &#8216;Fast&#8217; Reversal Is Coming Amid 174% Surge This Year And China Ant</a>
Trump has also hinted at his expectation for Putin to be open to a deal. However, the details of how he intends to bring both parties to the negotiation table and the terms of the potential agreement remain undisclosed.
Why It Matters: Putin also disclosed that he has not had any interaction with the deposed Syrian President Bashar al-Assad, who sought refuge in Moscow earlier this month. &#8220;I haven&#8217;t seen President Assad since his arrival in Moscow,&#8221; Putin stated. He also mentioned his plans to meet with Assad to discuss various matters, including the case of Austin Tice, the American journalist who has been missing. Earlier, Trump <a href="https://www.benzinga.com/news/global/24/12/42380085/trump-on-assads-fall-putin-was-not-interested-in-protecting-him-any-longer">commented on Putin&#8217;s lack of interest</a> in protecting Assad following the dictator&#8217;s fall.
Meanwhile, a book by journalist Bob Woodward in October<a href="https://www.benzinga.com/general/politics/24/10/41235596/trump-secretly-stayed-in-contact-with-putin-after-leaving-office-upcoming-bob-woodward-book-alle"> reportedly alleged that Trump and Russian President </a>Putin have spoken as many as seven times since 2021.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42516580/ionq-quantum-computing-and-rigetti-computing-shares-are-soaring-monday-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What&#8217;s Going On?</a>
Image via Kremlin

Politics

Russian President Says He's Willing To Meet Trump 'At Any Time' For Dialogue

Baird analyst Mark Altschwager maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $72.

BIRK

Baird Maintains Outperform on Birkenstock Holding, Raises Price Target to $72

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

"We are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation earlier this year, and we look forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January," said Katarina Luptakova, M.D., chief medical officer of Xilio.
"In addition, the preliminary Phase 1 data we reported today for XTX301, our tumor-activated IL-12, highlight its promising clinical profile, including no dose-limiting toxicities reported to date and consistent interferon gamma signaling observed throughout treatment cycles."

Xilio To Present Initial Data From Its Ongoing Phase 2 Trial For Vilastobart At ASCO GI; Reports Preliminary Phase 1 Data For XTX301 Showing Improved Tolerability Profile Over Historical Data For rhIL-12

Deutsche Bank analyst David Begleiter maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $150 to $145.

Deutsche Bank Maintains Buy on PPG Indus, Lowers Price Target to $145

Schwab Municipal Bond ETF declares $0.146 dividend

Schwab Municipal Bond ETF declares monthly distribution of $0.1383

Schwab Municipal Bond ETF declares monthly distribution of $0.1481

Schwab Municipal Bond ETF declares monthly distribution of $0.152

Schwab Municipal Bond ETF declares monthly distribution of $0.1413

Schwab Municipal Bond ETF declares monthly distribution of $0.1574

Schwab Municipal Bond ETF declares monthly distribution of $0.075

SCMB: Schwab Offers Low Cost Municipal Bond ETF But Not Great Results

Schwab Municipal Bond ETF declares monthly distribution of $0.0702

SCMB

Press Releases

Schwab Asset Management Announces ETF Share Splits

FNDA

FNDB

FNDX

SCHA

SCHB

SCHD

SCHF

SCHG

SCHI

SCHJ

SCHK

SCHM

SCHO

SCHP

SCHR

SCHV

SCHW

SCHX

SCHZ

SCYB

Comments

Schwab Strategic Trust Schwab Municipal Bond ETF

News

Latest news for Schwab Strategic Trust Schwab Municipal Bond ETF (ARCA:SCMB)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga